Novo Nordisk (NVO.US) Capital Markets Day falls flat: CEO admits too many promises, too little delivery, must rebuild investor confidence.

Zhito Finance APP has learned that Novo Nordisk (NVO.US) CEO Mike Doustdar said in an interview on Tuesday that the company must do more to rebuild investor confidence, as the maker of Ozempic's largest drug will face a patent cliff in the early part of the next decade.